Please enable JavaScript to continue using this application.

Compare $ARCT vs $GALT | Chartloom

Compare

$ARCT vs $GALT

Arcturus Therapeutics Holdings Inc · Galectin Therapeutics Inc

ARCT

Arcturus Therapeutics Holdings Inc

GALT

Galectin Therapeutics Inc

Compare $ARCT vs $GALT

Comparing Arcturus Therapeutics Holdings Inc and Galectin Therapeutics Inc

ARCTArcturus Therapeutics Holdings Inc

GALTGalectin Therapeutics Inc

ARCTArcturus Therapeutics Holdings Inc

Market cap

$390M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

21.64x

Rev growth (TTM)

-76.0%

YTD performance

119.8%

52W performance

-35.2%

FCF yield

-18.7%

GALTGalectin Therapeutics Inc

Market cap

$259M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-2.7%

52W performance

-16.9%

FCF yield

-6.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ARCT

GALT

Detailed metrics comparison

ARCT

Arcturus Therapeutics Holdings Inc

GALT

Galectin Therapeutics Inc

Market Cap

ARCT$390M

GALT$259M

Enterprise Value

ARCT$199M

GALT$384M

Price

ARCT$13.74

GALT$3.94

P/E Ratio

ARCTN/A

GALTN/A

P/S Ratio

ARCT13.30x

GALT0.00x

EV/Sales

ARCT6.78x

GALT0.00x

EV/EBITDA

ARCT1.82x

GALT0.00x

P/B Ratio

ARCT2.16x

GALT150.12x

P/FCF Ratio

ARCTN/A

GALTN/A

EV/FCF

ARCT-2.73x

GALT-24.16x

PEG Ratio

ARCTN/A

GALTN/A

Forward P/E (NTM)

ARCTN/A

GALTN/A

Forward P/S (NTM)

ARCT21.64x

GALTN/A

Revenue (TTM)

ARCT$29M

GALT$0

Revenue Growth (YoY)

ARCT-76.0%

GALTN/A

Forward Rev Growth

ARCT107.7%

GALT0.0%

Gross Margin (TTM)

ARCT0.0%

GALT0.0%

Operating Margin (TTM)

ARCT0.0%

GALT0.0%

EBITDA Margin (TTM)

ARCT-339.0%

GALT0.0%

Net Margin (TTM)

ARCT-317.6%

GALT0.0%

FCF Margin (TTM)

ARCT-248.6%

GALTN/A

Net Income (TTM)

ARCT$-93M

GALT$-28M

FCF (TTM)

ARCT$-73M

GALT$-16M

EPS (TTM)

ARCT-$3.28

GALT-$0.43

ROE (TTM)

ARCT-4654.0%

GALT-25862.0%

ROA (TTM)

ARCT-3646.0%

GALT-17683.0%

ROIC (TTM)

ARCT-4654.0%

GALT-11607.0%

Cash

ARCT$191M

GALT$13M

Debt

ARCT$0

GALT$138M

Net Cash/Debt

ARCT$191M

GALT$-124M

Current Ratio (TTM)

ARCT5.88x

GALT0.10x

Quick Ratio (TTM)

ARCT5.76x

GALT0.09x

Debt/Equity (TTM)

ARCT0.00x

GALT11.09x

Debt/Assets (TTM)

ARCT0.0%

GALT0.0%

Interest Coverage (TTM)

ARCTN/A

GALTN/A

Net Debt/EBITDA (TTM)

ARCT0.00x

GALT0.00x

Beta

ARCT2.60

GALT0.50

52W Performance

ARCT-35.2%

GALT-16.9%

YTD Performance

ARCT119.8%

GALT-2.7%

% from 52W High

ARCT-43.2%

GALT-44.7%

% from 52W Low

ARCT149.8%

GALT94.6%

Asset Turnover (TTM)

ARCT0.11x

GALT0.00x

FCF Yield (TTM)

ARCT-18.7%

GALT-6.1%

Earnings Yield (TTM)

ARCT-23.9%

GALT-10.8%

Dividend Yield (TTM)

ARCTN/A

GALTN/A

Rule of 40

ARCT-324.5

GALT0.0

EV/GP/RG

ARCTN/A

GALTN/A

Ticker research

View ARCT research View GALT research

Metric	ARCT Arcturus Therapeutics Holdings Inc	GALT Galectin Therapeutics Inc
Market & Valuation
Market Cap	$390M	$259M
Enterprise Value	$199M	$384M
Price	$13.74	$3.94
P/E Ratio	N/A	N/A
P/S Ratio	13.30x	0.00x
EV/Sales	6.78x	0.00x
EV/EBITDA	1.82x	0.00x
P/B Ratio	2.16x	150.12x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.73x	-24.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	21.64x	N/A
Revenue & Growth
Revenue (TTM)	$29M	$0
Revenue Growth (YoY)	-76.0%	N/A
Forward Rev Growth	107.7%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-339.0%	0.0%
Net Margin (TTM)	-317.6%	0.0%
FCF Margin (TTM)	-248.6%	N/A
Net Income (TTM)	$-93M	$-28M
FCF (TTM)	$-73M	$-16M
EPS (TTM)	-$3.28	-$0.43
ROE (TTM)	-4654.0%	-25862.0%
ROA (TTM)	-3646.0%	-17683.0%
ROIC (TTM)	-4654.0%	-11607.0%
Financial Health
Cash	$191M	$13M
Debt	$0	$138M
Net Cash/Debt	$191M	$-124M
Current Ratio (TTM)	5.88x	0.10x
Quick Ratio (TTM)	5.76x	0.09x
Debt/Equity (TTM)	0.00x	11.09x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.60	0.50
52W Performance	-35.2%	-16.9%
YTD Performance	119.8%	-2.7%
% from 52W High	-43.2%	-44.7%
% from 52W Low	149.8%	94.6%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.00x
FCF Yield (TTM)	-18.7%	-6.1%
Earnings Yield (TTM)	-23.9%	-10.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-324.5	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ARCT research	View GALT research

Valuation

P/S Ratio

GALT

0.00x

ARCT

13.30x

EV/FCF

GALT

-24.16x

ARCT

-2.73x

Growth & revenue

Revenue Growth TTM

ARCT

-76.0%

Forward Revenue Growth

ARCT

107.7%

GALT

0.0%

Profitability & performance

Gross Margin

ARCT

0.0%

GALT

0.0%

ROE

ARCT

-4654.0%

GALT

-25862.0%

FCF Yield %

GALT

-6.1%

ARCT

-18.7%

52-Week Performance

GALT

-16.9%

ARCT

-35.2%

Detailed metrics comparison

ARCT

Arcturus Therapeutics Holdings Inc

GALT

Galectin Therapeutics Inc

Market Cap

ARCT$390M

GALT$259M

Enterprise Value

ARCT$199M

GALT$384M

Price

ARCT$13.74

GALT$3.94

P/E Ratio

ARCTN/A

GALTN/A

P/S Ratio

ARCT13.30x

GALT0.00x

EV/Sales

ARCT6.78x

GALT0.00x

EV/EBITDA

ARCT1.82x

GALT0.00x

P/B Ratio

ARCT2.16x

GALT150.12x

P/FCF Ratio

ARCTN/A

GALTN/A

EV/FCF

ARCT-2.73x

GALT-24.16x

PEG Ratio

ARCTN/A

GALTN/A

Forward P/E (NTM)

ARCTN/A

GALTN/A

Forward P/S (NTM)

ARCT21.64x

GALTN/A

Revenue (TTM)

ARCT$29M

GALT$0

Revenue Growth (YoY)

ARCT-76.0%

GALTN/A

Forward Rev Growth

ARCT107.7%

GALT0.0%

Gross Margin (TTM)

ARCT0.0%

GALT0.0%

Operating Margin (TTM)

ARCT0.0%

GALT0.0%

EBITDA Margin (TTM)

ARCT-339.0%

GALT0.0%

Net Margin (TTM)

ARCT-317.6%

GALT0.0%

FCF Margin (TTM)

ARCT-248.6%

GALTN/A

Net Income (TTM)

ARCT$-93M

GALT$-28M

FCF (TTM)

ARCT$-73M

GALT$-16M

EPS (TTM)

ARCT-$3.28

GALT-$0.43

ROE (TTM)

ARCT-4654.0%

GALT-25862.0%

ROA (TTM)

ARCT-3646.0%

GALT-17683.0%

ROIC (TTM)

ARCT-4654.0%

GALT-11607.0%

Cash

ARCT$191M

GALT$13M

Debt

ARCT$0

GALT$138M

Net Cash/Debt

ARCT$191M

GALT$-124M

Current Ratio (TTM)

ARCT5.88x

GALT0.10x

Quick Ratio (TTM)

ARCT5.76x

GALT0.09x

Debt/Equity (TTM)

ARCT0.00x

GALT11.09x

Debt/Assets (TTM)

ARCT0.0%

GALT0.0%

Interest Coverage (TTM)

ARCTN/A

GALTN/A

Net Debt/EBITDA (TTM)

ARCT0.00x

GALT0.00x

Beta

ARCT2.60

GALT0.50

52W Performance

ARCT-35.2%

GALT-16.9%

YTD Performance

ARCT119.8%

GALT-2.7%

% from 52W High

ARCT-43.2%

GALT-44.7%

% from 52W Low

ARCT149.8%

GALT94.6%

Asset Turnover (TTM)

ARCT0.11x

GALT0.00x

FCF Yield (TTM)

ARCT-18.7%

GALT-6.1%

Earnings Yield (TTM)

ARCT-23.9%

GALT-10.8%

Dividend Yield (TTM)

ARCTN/A

GALTN/A

Rule of 40

ARCT-324.5

GALT0.0

EV/GP/RG

ARCTN/A

GALTN/A

Ticker research

View ARCT research View GALT research

Metric	ARCT Arcturus Therapeutics Holdings Inc	GALT Galectin Therapeutics Inc
Market & Valuation
Market Cap	$390M	$259M
Enterprise Value	$199M	$384M
Price	$13.74	$3.94
P/E Ratio	N/A	N/A
P/S Ratio	13.30x	0.00x
EV/Sales	6.78x	0.00x
EV/EBITDA	1.82x	0.00x
P/B Ratio	2.16x	150.12x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.73x	-24.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	21.64x	N/A
Revenue & Growth
Revenue (TTM)	$29M	$0
Revenue Growth (YoY)	-76.0%	N/A
Forward Rev Growth	107.7%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-339.0%	0.0%
Net Margin (TTM)	-317.6%	0.0%
FCF Margin (TTM)	-248.6%	N/A
Net Income (TTM)	$-93M	$-28M
FCF (TTM)	$-73M	$-16M
EPS (TTM)	-$3.28	-$0.43
ROE (TTM)	-4654.0%	-25862.0%
ROA (TTM)	-3646.0%	-17683.0%
ROIC (TTM)	-4654.0%	-11607.0%
Financial Health
Cash	$191M	$13M
Debt	$0	$138M
Net Cash/Debt	$191M	$-124M
Current Ratio (TTM)	5.88x	0.10x
Quick Ratio (TTM)	5.76x	0.09x
Debt/Equity (TTM)	0.00x	11.09x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.60	0.50
52W Performance	-35.2%	-16.9%
YTD Performance	119.8%	-2.7%
% from 52W High	-43.2%	-44.7%
% from 52W Low	149.8%	94.6%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.00x
FCF Yield (TTM)	-18.7%	-6.1%
Earnings Yield (TTM)	-23.9%	-10.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-324.5	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ARCT research	View GALT research